Literature DB >> 28589253

Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.

Christian Uprimny1, Alexander Stephan Kroiss2, Josef Fritz3, Clemens Decristoforo2, Dorota Kendler2, Elisabeth von Guggenberg2, Bernhard Nilica2, Johanna Maffey-Steffan2, Gianpaolo di Santo2, Jasmin Bektic4, Wolfgang Horninger4, Irene Johanna Virgolini2.   

Abstract

PURPOSE: PET/CT using 68Ga-labelled prostate-specific membrane antigen PSMA-11 (HBEDD-CC) has emerged as a promising imaging method in the diagnostic evaluation of prostate cancer (PC) patients with biochemical recurrence. However, assessment of local recurrence (LR) may be limited by intense physiologic tracer accumulation in the urinary bladder on whole-body scans, normally conducted 60 min post-tracer injection (p.i.). It could be shown on early dynamic imaging studies that 68Ga-PSMA-11 uptake in PC lesions occurs earlier than tracer accumulation in the urinary bladder. This study aims to investigate whether early static PET acquisition increases detection rate of local recurrence on 68Ga-PSMA-11 PET/CT in comparison to PET imaging 60 min p.i..
METHODS: 203 consecutive PC patients with biochemical failure referred to 68Ga-PSMA-11 PET/CT were analysed retrospectively (median prostate specific antigen (PSA) value: 1.44 ng/ml). In addition to whole-body PET/CT scans 60 min p.i., early static imaging of the pelvis was performed, starting at a median time of 283 s p.i. (range: 243-491 s). Assessment was based on visual analysis and calculation of maximum standardized uptake value (SUVmax) of pathologic lesions present in the pelvic area found on early PET imaging and on 60 min-PET scans.
RESULTS: 26 patients (12.8%) were judged positive for LR on PET scans 60 min p.i. (median SUVmax: 10.8; range: 4.7-40.9), whereas 50 patients (24.6%) revealed a lesion suggestive of LR on early PET imaging (median SUVmax: 5.9; range: 2.9-17.6), resulting in a significant rise in detection rate (p < 0.001). Equivocal findings on PET scans 60 min p.i. decreased significantly with the help of early imaging (15.8% vs. 4.5% of patients; p < 0.001). Tracer activity in the urinary bladder with a median SUVmax of 8.2 was present in 63 patients on early PET scans (31.0%). However, acquisition starting time of early PET scans differed significantly in the patient groups with and without urinary bladder activity (median starting time of 321 vs. 275 s p.i.; range: 281-491 vs. 243-311 s p.i.; p < 0.001). Median SUVmax value of lesions suggestive of LR on early images was significantly higher in comparison to gluteal muscle, inguinal vessels and seminal vesicle/anastomosis (median SUVmax: 5.9 vs. 1.9, 4.0 and 2.4, respectively).
CONCLUSIONS: Performance of early imaging in 68Ga-PSMA-11 PET/CT in addition to whole-body scans 60 min p.i. increases the detection rate of local recurrence in PC patients with biochemical recurrence. Acquisition of early PET images should be started as early as 5 min p.i. in order to avoid disturbing tracer activity in the urinary bladder occuring at a later time point.

Entities:  

Keywords:  68Ga-PSMA-11 PET/CT; Biochemical relapse; Early PET imaging; Local recurrence; Prostate canceer

Mesh:

Substances:

Year:  2017        PMID: 28589253     DOI: 10.1007/s00259-017-3743-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  36 in total

Review 1.  Role of MRI in follow-up after focal therapy for prostate carcinoma.

Authors:  Pieter J De Visschere; Gert O De Meerleer; Jurgen J Fütterer; Geert M Villeirs
Journal:  AJR Am J Roentgenol       Date:  2010-06       Impact factor: 3.959

2.  The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer.

Authors:  Laura Evangelista; Marino Cimitan; Marina Hodolič; Tanja Baseric; Jure Fettich; Eugenio Borsatti
Journal:  Abdom Imaging       Date:  2015-10

3.  (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

Authors:  Francesco Ceci; Christian Uprimny; Bernhard Nilica; Llanos Geraldo; Dorota Kendler; Alexander Kroiss; Jasmin Bektic; Wolfgang Horninger; Peter Lukas; Clemens Decristoforo; Paolo Castellucci; Stefano Fanti; Irene J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-15       Impact factor: 9.236

4.  The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer.

Authors:  Ali Afshar-Oromieh; Lars Peter Sattler; Walter Mier; Boris A Hadaschik; Jürgen Debus; Tim Holland-Letz; Klaus Kopka; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2017-01-06       Impact factor: 10.057

5.  Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI.

Authors:  Martin T Freitag; Jan P Radtke; Ali Afshar-Oromieh; Matthias C Roethke; Boris A Hadaschik; Martin Gleave; David Bonekamp; Klaus Kopka; Matthias Eder; Thorsten Heusser; Marc Kachelriess; Kathrin Wieczorek; Christos Sachpekidis; Paul Flechsig; Frederik Giesel; Markus Hohenfellner; Uwe Haberkorn; Heinz-Peter Schlemmer; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-17       Impact factor: 9.236

6.  68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.

Authors:  Christian Uprimny; Alexander Stephan Kroiss; Clemens Decristoforo; Josef Fritz; Elisabeth von Guggenberg; Dorota Kendler; Lorenza Scarpa; Gianpaolo di Santo; Llanos Geraldo Roig; Johanna Maffey-Steffan; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-31       Impact factor: 9.236

7.  Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.

Authors:  Ali Afshar-Oromieh; Henrik Hetzheim; Wolfgang Kübler; Clemens Kratochwil; Frederik L Giesel; Thomas A Hope; Matthias Eder; Michael Eisenhut; Klaus Kopka; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-03       Impact factor: 9.236

8.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236

Review 9.  Early salvage radiotherapy following radical prostatectomy.

Authors:  David Pfister; Michel Bolla; Alberto Briganti; Peter Carroll; Cesare Cozzarini; Steven Joniau; Hein van Poppel; Mack Roach; Andrew Stephenson; Thomas Wiegel; Michael J Zelefsky
Journal:  Eur Urol       Date:  2013-08-15       Impact factor: 20.096

10.  (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.

Authors:  Florian Sterzing; Clemens Kratochwil; Hannah Fiedler; Sonja Katayama; Gregor Habl; Klaus Kopka; Ali Afshar-Oromieh; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-25       Impact factor: 9.236

View more
  15 in total

1.  [68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence.

Authors:  Mark A Green; Gary D Hutchins; Clinton D Bahler; Mark Tann; Carla J Mathias; Wendy Territo; Justin Sims; Heather Polson; David Alexoff; William C Eckelman; Hank F Kung; James W Fletcher
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

2.  68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis.

Authors:  Christos Sachpekidis; Leyun Pan; Boris A Hadaschik; Klaus Kopka; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

3.  Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [68Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients.

Authors:  Christian Uprimny; Steffen Bayerschmidt; Alexander Stephan Kroiss; Josef Fritz; Bernhard Nilica; Anna Svirydenka; Clemens Decristoforo; Gianpaolo di Santo; Elisabeth von Guggenberg; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-08       Impact factor: 9.236

4.  68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Authors:  Alexander Heinzel; Dima Boghos; Felix M Mottaghy; Florian Gaertner; Markus Essler; Dirk von Mallek; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-29       Impact factor: 9.236

5.  18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer.

Authors:  Christos Sachpekidis; A Afshar-Oromieh; K Kopka; D S Strauss; L Pan; U Haberkorn; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-14       Impact factor: 9.236

6.  Combined Early and Late [68Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels.

Authors:  M Hohberg; C Kobe; P Täger; J Hammes; M Schmidt; F Dietlein; M Wild; A Heidenreich; A Drzezga; M Dietlein
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

7.  Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.

Authors:  Christian Uprimny; Steffen Bayerschmidt; Alexander Stephan Kroiss; Josef Fritz; Bernhard Nilica; Hanna Svirydenka; Clemens Decristoforo; Elisabeth von Guggenberg; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  J Nucl Med       Date:  2021-03-12       Impact factor: 10.057

Review 8.  PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.

Authors:  Sebastian Zschaeck; Fabian Lohaus; Marcus Beck; Gregor Habl; Stephanie Kroeze; Constantinos Zamboglou; Stefan Alexander Koerber; Jürgen Debus; Tobias Hölscher; Peter Wust; Ute Ganswindt; Alexander D J Baur; Klaus Zöphel; Nikola Cihoric; Matthias Guckenberger; Stephanie E Combs; Anca Ligia Grosu; Pirus Ghadjar; Claus Belka
Journal:  Radiat Oncol       Date:  2018-05-11       Impact factor: 3.481

9.  Role of Early Dynamic Positron Emission Tomography/Computed Tomography with 68Ga-prostate-specific Membrane Antigen-HBED-CC in Patients with Adenocarcinoma Prostate: Initial Results.

Authors:  Gazala Perveen; Geetanjali Arora; Nishikant Avinash Damle; Meghana Prabhu; Saurabh Arora; Madhavi Tripathi; Chandrasekhar Bal; Praveen Kumar; Rajeev Kumar; Prabhjot Singh
Journal:  Indian J Nucl Med       Date:  2018 Apr-Jun

10.  Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer.

Authors:  Andrew Barakat; Basel Yacoub; Maria El Homsi; Amro Saad Aldine; Albert El Hajj; Mohamad B Haidar
Journal:  Sci Rep       Date:  2020-02-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.